908 Devices Inc.
Close on Oct 19, 2026
- Market cap
- $431.23M
- P/E (TTM)
- –
- Dividend yield
- –
About 908 Devices
Laboratory Analytical Instruments, SIC 3826
908 Devices develops and manufactures portable devices for chemical analysis at the point of need using mass spectrometry and optical spectroscopy technologies. Its portfolio includes handheld instruments such as the MX908, ThreatID, ProtectIR, XplorIR, and VipIR, alongside sampling consumables, extended warranty plans, on-site training, and round-the-clock technical support. The business serves government and life sciences markets, providing measurement tools to civilian first responders, military personnel, hazmat teams, customs and border agents, and law enforcement officers.
The company has deployed more than 3,700 devices across all fifty U.S. states and five continents to over 700 customer accounts. Commercial reach includes a direct North American sales organization and more than 64 domestic and international distribution partners. Primary manufacturing takes place in Danbury, Connecticut, supported by machining sites in Stamford, Connecticut, and Georgetown, Massachusetts, as well as research facilities in Burlington, Massachusetts, and Danbury. The text does not specify a corporate headquarters location.
Summary of the business section of 908 Devices's latest annual report, written by StockData.
Company profile
Company
- Legal name
- 908 Devices Inc.
- Headquarters
- Burlington, MA
- Address
- 44 Third Avenue 01803
- Phone
- (978) 729-4478
- Employees
- 172, Dec 31, 2025
- Industry
- Laboratory Analytical Instruments
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers, LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- MASS
- Exchange
- Nasdaq
- IPO date
- Dec 18, 2020
- Shares outstanding
- 41M, Aug 7, 2026
- Public float
- $194.90M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1555279
- CUSIP
- 65443P102
- ISIN
- US65443P1021
- EIN
- 45-4524096
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Kevin J. Knopp | President and CEO, Director | 1,097,191 |
| John Kenneweg | SVP, Sales & Product Marketing | 57,784 |
| Joseph H. Griffith IV | Chief Financial Officer | 121,497 |
| Kolawole A. Otitoju | Chief Bus. & Strategy Officer | – |
| Kevin J. McCallion | SVP, Products and Production | 44,925 |
| Mark S. Levine | Chief Legal and Admin. Officer | – |
| Michael S. Turner | Chief Legal & Admin Officer | 0 |
| Christopher D. Brown | Director | 775,559 |
| Brandi C. Vann | Director | 5,192 |
| Michele M. Leonhart | Director | 27,054 |
| Anthony Hunt | Director | 44,168 |
| E. Kevin Hrusovsky | Director | 495,065 |
| Mark Spoto | Director | 92,945 |
| Fenel M. Eloi | Director | 40,897 |
| Keith Crandell | Director | 5,764,419 |
| Jeffrey P. George | Director | 26,814 |
| Marcia Eisenberg | Director | 25,957 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Kevin J. Knopp, Ph.D. was our PEO for bothyears presented. | $1.55M | $3.05M | $1.24M | $47 | – |
| FY2024 Kevin J. Knopp, Ph.D. was our PEO for bothyears presented. | $1.99M | $29.39K | $1.22M | $20 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 172 full-time employees, of which 35 work in sales, sales support and marketing, 43 work in engineering and research and development, 62 work in manufacturing, operations and service and 32 work in general and administrative.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 6, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 4, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Apr 30, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Dec 18, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Dec 17, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |